Renata has voluntarily withdrawn Valdex (Valdecoxib),
a Cox-2 Inhibitor from the market with effect from April 8, 2005.
This decision follows the request made by US FDA to Pfizer Inc to
withdraw Bextra from the US market.
http://www.medicalnewstoday.com/medicalnews.php?newsid=22486&nfid=rssfeeds
Pfizer has withdrawn Bextra from US and
Europe.
As far as Renata is concerned the
decision to withdraw Valdex will not affect company earnings to any
significant degree. Moreover, another molecule, viz.,
Aceclofenac will be launched by May 2005 to replace Valdecoxib.
